Picture of Mauna Kea Technologies SA logo

ALMKT — Mauna Kea Technologies SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

Brief: Mauna Kea Technologies Says CONTACT 2 Study Met Its Clinical Endpoints

Nov 6 (Reuters) - MAUNA KEA TECHNOLOGIES SAS  MKEA.PA :
    * PIVOTAL STUDY ON CONTACT 2 PANCREATIC CYSTS HAS MET ALL OF
ITS
PRIMARY AND SECONDARY CLINICAL ENDPOINTS
    * SIGNIFICANTLY HIGHER DIAGNOSTIC PERFORMANCE OF CELLVIZIO
COMPARED TO THE STANDARD TECHNIQUE
    * CELLVIZIO MADE A CONCLUSIVE AND CORRECT DIAGNOSIS IN 21 OF
THE
23 PATIENTS

Source text for Eikon:  ID:nBw51KPwVa 
Further company coverage:  MKEA.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))

Recent news on Mauna Kea Technologies SA

See all news